Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells.

Autor: Volta L; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland.; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland., Myburgh R; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland.; Phire/ATLyphe, Wyss Zurich Translational Center ETH Zürich/University of Zürich Zürich Switzerland., Hofstetter M; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland.; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland., Koch C; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland.; Department of Biosystems Science and Engineering ETH Zurich Basel Switzerland., Kiefer JD; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland., Gobbi C; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Manfredi F; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Zimmermann K; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Kaufmann P; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Fazio S; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Pellegrino C; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Russkamp NF; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Villars D; Phire/ATLyphe, Wyss Zurich Translational Center ETH Zürich/University of Zürich Zürich Switzerland., Matasci M; Philochem AG Otelfingen Switzerland., Maurer M; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Mueller J; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Schneiter F; Department of Biosystems Science and Engineering ETH Zurich Basel Switzerland., Büschl P; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Harrer N; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Mock J; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland.; Philochem AG Otelfingen Switzerland., Balabanov S; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Nombela-Arrieta C; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland., Schroeder T; Department of Biosystems Science and Engineering ETH Zurich Basel Switzerland., Neri D; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland.; Philochem AG Otelfingen Switzerland., Manz MG; Department of Medical Oncology and Hematology University and University Hospital Zürich Zürich Switzerland.; Comprehensive Cancer Center Zürich University and University Hospitals Zürich Zürich Switzerland.

Publikováno v: HemaSphere [Hemasphere] 2024 Nov 19; Vol. 8 (11), pp. e70055. Date of Electronic Publication: 2024 Nov 19 (Print Publication: 2024).